Laura H Jacobson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8574871/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hypocretins (orexins): The ultimate translational neuropeptides. Journal of Internal Medicine, 2022, 291, 533-556.	2.7	42
2	Differential sleep/wake response and sex differences following acute suvorexant, MKâ€1064 and zolpidem administration in the rTg4510 mouse model of tauopathy. British Journal of Pharmacology, 2022, 179, 3403-3417.	2.7	5
3	Losing sleep with age. Science, 2022, 375, 816-817.	6.0	4
4	Orexin Signaling: A Complex, Multifaceted Process. Frontiers in Cellular Neuroscience, 2022, 16, 812359.	1.8	15
5	Decreased Orexin Receptor 1 mRNA Expression in the Locus Coeruleus in Both Tau Transgenic rTg4510 and Tau Knockout Mice and Accompanying Ascending Arousal System Tau Invasion in rTg4510. Journal of Alzheimer's Disease, 2021, 79, 693-708.	1.2	7
6	Manipulation of rapid eye movement sleep via orexin and GABAA receptor modulators differentially affects fear extinction in mice: effect of stable versus disrupted circadian rhythm. Sleep, 2021, 44, .	0.6	10
7	Reward motivation and cognitive flexibility in tau null-mutation mice. Neurobiology of Aging, 2021, 100, 106-117.	1.5	1
8	Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360. Journal of Medicinal Chemistry, 2021, 64, 4677-4696.	2.9	9
9	Development of a LC-ESI-MRM method for the absolute quantification of orexin A in the CSF of individual mice. Medicine in Drug Discovery, 2021, 11, 100102.	2.3	3
10	Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease. Journal of Medicinal Chemistry, 2021, 64, 15262-15279.	2.9	14
11	Hypnotics with novel modes of action. British Journal of Clinical Pharmacology, 2020, 86, 244-249.	1.1	25
12	Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Medicine Reviews, 2020, 53, 101332.	3.8	39
13	Circadian disruption impairs fear extinction and memory of conditioned safety in mice. Behavioural Brain Research, 2020, 393, 112788.	1.2	4
14	Novel alterations in corneal neuroimmune phenotypes in mice with central nervous system tauopathy. Journal of Neuroinflammation, 2020, 17, 136.	3.1	11
15	Sex differences in mouse models of fear inhibition: Fear extinction, safety learning, and fear–safety discrimination. British Journal of Pharmacology, 2019, 176, 4149-4158.	2.7	40
16	Separating Probability and Reversal Learning in a Novel Probabilistic Reversal Learning Task for Mice. Frontiers in Behavioral Neuroscience, 2019, 13, 270.	1.0	23
17	The Gamma-Aminobutyric Acid B Receptor in Depression and Reward. Biological Psychiatry, 2018, 83, 963-976.	0.7	51
18	Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2195-2200.	1.0	10

LAURA H JACOBSON

#	Article	IF	CITATIONS
19	The social defeat/overcrowding murine psychosocial stress model results in a pharmacologically reversible body weight gain but not depression - related behaviours. Neurobiology of Stress, 2018, 9, 176-187.	1.9	8
20	The <scp>BACE</scp> â€l inhibitor <scp>CNP</scp> 520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	112
21	Selective Na _V 1.1 activation rescues Dravet syndrome mice from seizures and premature death. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8077-E8085.	3.3	105
22	Ablation of tau causes an olfactory deficit in a murine model of Parkinson's disease. Acta Neuropathologica Communications, 2018, 6, 57.	2.4	11
23	Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABAB1a but not GABAB1b subunit isoforms. Psychopharmacology, 2017, 234, 1511-1523.	1.5	9
24	Orexin Receptor Antagonists. Current Sleep Medicine Reports, 2017, 3, 342-353.	0.7	1
25	Orexin OX2 Receptor Antagonists as Sleep Aids. Current Topics in Behavioral Neurosciences, 2016, 33, 105-136.	0.8	28
26	Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice. Scientific Reports, 2016, 6, 21917.	1.6	56
27	Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor–treated APP transgenic mice. Neurobiology of Aging, 2016, 45, 50-60.	1.5	15
28	Neurological Dysfunction in Early Maturity of a Model for Niemann–Pick C1 Carrier Status. Neurotherapeutics, 2016, 13, 614-622.	2.1	17
29	Differential roles of GABAB1 subunit isoforms on locomotor responses to acute and repeated administration of cocaine. Behavioural Brain Research, 2016, 298, 12-16.	1.2	10
30	A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Molecular Neurodegeneration, 2015, 10, 44.	4.4	102
31	Discovery of 1 H -pyrazolo[3,4- b]pyridines as potent dual orexin receptor antagonists (DORAs). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5555-5560.	1.0	14
32	Suvorexant for the treatment of insomnia. Expert Review of Clinical Pharmacology, 2014, 7, 711-730.	1.3	40
33	Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: Structure based design and in vivo reduction of amyloid β-peptides. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5300-5306.	1.0	20
34	Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia. Journal of Medicinal Chemistry, 2013, 56, 7590-7607.	2.9	82
35	Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?. Neuropeptides, 2013, 47, 477-488.	0.9	98
36	Enhanced Proteolytic Clearance of Plasma AÎ ² by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain Al ² in Mice, Journal of Neuroscience, 2013, 33, 2457-2464	1.7	53

LAURA H JACOBSON

#	Article	IF	CITATIONS
37	Kinetic properties of "dual―orexin receptor antagonists at OX1R and OX2R orexin receptors. Frontiers in Neuroscience, 2013, 7, 230.	1.4	28
38	Distinct effects of IPSU and suvorexant on mouse sleep architecture. Frontiers in Neuroscience, 2013, 7, 235.	1.4	33
39	Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides. Journal of Medicinal Chemistry, 2012, 55, 3364-3386.	2.9	91
40	BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System. PLoS ONE, 2012, 7, e31084.	1.1	68
41	Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 384, 565-581.	1.4	6
42	The Second-Generation Active AÂ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects. Journal of Neuroscience, 2011, 31, 9323-9331.	1.7	167
43	Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded rats. Psychopharmacology, 2010, 211, 197-208.	1.5	16
44	Effect of abomasal prebiotic supplementation on sheep faecal microbiota. New Zealand Journal of Agricultural Research, 2010, 53, 99-108.	0.9	1
45	Genetic Approaches to Modeling Anxiety in Animals. Current Topics in Behavioral Neurosciences, 2009, 2, 161-201.	0.8	25
46	Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12926-12931.	3.3	249
47	mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Molecular Psychiatry, 2008, 13, 970-979.	4.1	116
48	Correlation of cellular changes and spatial memory during aging in rats. Experimental Gerontology, 2008, 43, 929-938.	1.2	31
49	Evaluation of the anxiolytic-like profile of the GABAB receptor positive modulator CGP7930 in rodents. Neuropharmacology, 2008, 54, 854-862.	2.0	65
50	Specific roles of GABAB(1) receptor isoforms in cognition. Behavioural Brain Research, 2007, 181, 158-162.	1.2	49
51	Behavioral evaluation of mice deficient in GABAB(1) receptor isoforms in tests of unconditioned anxiety. Psychopharmacology, 2007, 190, 541-553.	1.5	70
52	Feeling Strained? Influence of Genetic Background on Depression-Related Behavior in Mice: A Review. Behavior Genetics, 2007, 37, 171-213.	1.4	153
53	Differential Compartmentalization and Distinct Functions of GABAB Receptor Variants. Neuron, 2006, 50, 589-601.	3.8	289
54	A genetic upper limit to whole-body protein deposition in a strain of growing pigs1. Journal of Animal Science, 2006, 84, 3301-3309.	0.2	14

LAURA H JACOBSON

#	Article	IF	CITATIONS
55	GABAB(1) Receptor Isoforms Differentially Mediate the Acquisition and Extinction of Aversive Taste Memories. Journal of Neuroscience, 2006, 26, 8800-8803.	1.7	53
56	GABAB(1) Receptor Subunit Isoforms Exert a Differential Influence on Baseline but Not GABAB Receptor Agonist-Induced Changes in Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1317-1326.	1.3	23
57	Differential sensitivity to the motor and hypothermic effects of the GABAB receptor agonist baclofen in various mouse strains. Psychopharmacology, 2005, 179, 688-699.	1.5	38
58	Effect of feeding pasture-finished cattle different conserved forages on Escherichia coli in the rumen and faeces. Meat Science, 2002, 62, 93-106.	2.7	33
59	Effect of preslaughter feeding system on weight loss, gut bacteria, and the physicoâ€chemical properties of digesta in cattle. New Zealand Journal of Agricultural Research, 2000, 43, 351-361.	0.9	34
60	Partitioning psychological and physical sources of transport related stress in young cattle. Veterinary Journal, 1998, 155, 205-208.	0.6	24
61	Heart rate as a measure of adaptation to stress in cattle. Australian Veterinary Journal, 1996, 74, 471-472.	0.5	11
62	Salivary cortisol as an indicator of stress in sheep (<i>Ovis ovis</i>). New Zealand Veterinary Journal, 1995, 43, 248-248.	0.4	17
63	Electrical head-only stunning of fallow deer (Dama dama). New Zealand Veterinary Journal, 1994, 42, 38-39.	0.4	3